Pimecrolimus 1% cream for the treatment of seborrheic dermatitis: a systematic review of randomized controlled trials

Ang-Tiu, Charlene U.; Meghrajani, Chandra F; Maano, Clarita C

doi:10.1586/ecp.11.68

Cited by 27 publications

(17 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, 0.1% tacrolimus ointment is more effective at reducing symptoms of AD when compared with low-potency corticosteroids, 0.03% tacrolimus and 1% pimecrolimus cream (209). Clinical trials have shown benefit of both pimecrolimus and tacrolimus in seborrhoeic dermatitis, genital lichen sclerosus, intertriginous psoriasis and cutaneous lupus erythematosus and -only for tacrolimus -in resistant pruritus ani (210)(211)(212)(213)(214)(215)(216)(217)(218). Both substances can be used to treat localised forms of CP such as genital pruritus (219).…”

Section: Tacrolimus and Pimecrolimusmentioning

confidence: 99%

European S2k Guideline on Chronic Pruritus

Weißhaar¹,

Szepietowski²,

Dalgard³

et al. 2019

Acta Derm Venerol

250

209

View full text Add to dashboard Cite

ActaDV is a journal for clinical and experimental research in the field of dermatology and venereology and publishes highquality papers in English dealing with new observations on basic dermatological and venereological research, as well as clinical investigations. Each volume also features a number of review articles in special areas, as well as Correspondence to the Editor to stimulate debate. New books are also reviewed. The journal has rapid publication times.

show abstract

Section: Tacrolimus and Pimecrolimusmentioning

confidence: 99%

European S2k Guideline on Chronic Pruritus

Weißhaar¹,

Szepietowski²,

Dalgard³

et al. 2019

Acta Derm Venerol

250

209

View full text Add to dashboard Cite

show abstract

“…This mostly pertains to topical steroids that are used in clinical practice to rapidly reduce erythema (Gupta and Versteeg, 2017). When long-term control of the inflammatory response in seborrheic dermatitis is required topical use of the calcineurin inhibitors tacrolimus and pimecrolimus is advised (Ang-Tiu et al, 2012). Safety regarding carcinogenicity of these substances is extrapolated from data in atopic dermatitis and does not seem a reason of concern (Cook and Warshaw, 2009).…”

Section: Treatmentmentioning

confidence: 99%

Malassezia-Associated Skin Diseases, the Use of Diagnostics and Treatment

Saunte

Gaitanis

Hay

2020

Front. Cell. Infect. Microbiol.

139

110

View full text Add to dashboard Cite

Yeasts of the genus, Malassezia, formerly known as Pityrosporum, are lipophilic yeasts, which are a part of the normal skin flora (microbiome). Malassezia colonize the human skin after birth and must therefore, as commensals, be normally tolerated by the human immune system. The Malassezia yeasts also have a pathogenic potential where they can, under appropriate conditions, invade the stratum corneum and interact with the host immune system, both directly but also through chemical mediators. The species distribution on the skin and the pathogenetic potential of the yeast varies between different Malassezia related diseases such as head and neck dermatitis, seborrheic dermatitis, pityriasis versicolor, and Malassezia folliculitis. The diagnostic methods used to confirm the presence of Malassezia yeasts include direct microcopy, culture based methods (often a combination of morphological features of the isolate combined with biochemical test), molecular based methods such as Polymerase Chain Reaction techniques, and Matrix Assisted Laser Desorption/Ionization-Time Of Flight mass spectrometry and the chemical imprint method Raman spectroscopy. Skin diseases caused by Malassezia are usually treated with antifungal therapy and if there are associated inflammatory skin mechanisms this is often supplemented by anti-inflammatory therapy. The aim of this paper is to provide an overview of Malassezia related skin disease, diagnostic methods and treatment options.

show abstract

“…Mittlerweile wurde in RCT der erfolgreiche Einsatz von Pimecrolimus (Elidel ® ) und Tacrolimus (Protopic ® ) bei juckenden, inflammatorischen Dermatosen (z. B. intertriginöse Psoriasis, Pruritus ani, seborrhoisches Ekzem) bei 2 ϫ täglicher Anwendung beschrieben [46][47][48]. In Fallserien und Einzelfallberichten konnte ein antipruritischer Effekt bei Handekzem, genitalem Pruritus, cholestatischem Pruritus bei PBC und nephrogenem Pruritus belegt werden [44,45,49,50,213,214,244].…”

Section: Calcineurininhibitorenunclassified